In these intracranial astrocytoma models, the overall tumor size was decreased with BRAF inhibitor treatment, whereas no response was observed when administered with the wild-type BRAF control treatment (41). This evidence concerns the gene BRAF and astrocytoma (excluding glioblastoma).